| Theme |
Acute Liver Failure and Regenerative Medicine of the Liver |
| Title |
Current Status and Future Perspectives for Autologous Bone Marrow Cell Infusion Therapy for Liver Cirrhosis Patients |
| Author |
Shuji Terai |
Department of Gastroenterlogy and Hepatology, Yamaguchi University Graduate School of Medicine |
| Author |
Isao Sakaida |
Department of Gastroenterlogy and Hepatology, Yamaguchi University Graduate School of Medicine |
| [ Summary ] |
This article reviews recent translational research on the development of cell therapy using autologous bone marrow cells for liver cirrhosis patients. A clinical study of autologous bone marrow cell infusion (ABMI) therapy for liver cirrhosis patients began on Nov. 14, 2003. The study was based on the finding that bone marrow cell infusion into mice with cirrhosis was effective for improvement of liver fibrosis, liver function and survival rates. In clinical studies, the safety and effectiveness of ABMI therapy was shown in relation to previous studies. At this time 23 cases of ABMI therapy have been performed for LC patients. No major adverse effects have been noted due to ABMI therapy. ABMI therapy was also done on a global basis. From these results, ABMI therapy should be considered to be a novel treatment for LC patients. |